

CURRICULUM VITAE

Bahman Yousefi, Ph.D

Associate professor

Department of Clinical Biochemistry

Faculty of Medicine,

Tabriz University of Medical Sciences (TUMS),

Tabriz, Iran. Phone: +989149117624

Email: Bahmanusefi@gmail.com, yousefib@tbzmed.ac.ir

Webpages:

- <https://scholar.google.com/citations?user=-ucs1tIAAAAJ&hl=en>

- https://isid.research.ac.ir/Bahman_Yousefi

- <https://www.linkedin.com/in/dr-bahman-yousefi-aa877069/>

RESEARCH INTEREST

My research interest is focused on three main aspects of cancer biology: i) the study of how oncogenic signaling drives cancer metabolic adaptation mechanisms, modifying ii) the study of metabolic/signaling crosstalk between tumor cells and tumor microenvironment and iii) finding new strategies for cancer gene therapy. The final goal is to discover new molecules that can be exploited as therapeutic targets.

My place in the field: i) World's Top 1% Higley Cited Researcher according to Essential Science Indicators and Clarivate Analytics ii) First-Ranked among 409 biochemists that work in Iranian medical universities.

EDUCATIONS

- 2012 - 2016 Ph.D degree in Clinical Biochemistry, Tabriz University of Medical Sciences, Iran
Thesis: Role of the PPARs and its relation with PI3K/mTOR signaling pathway in doxorubicin resistant human chronic myeloid leukemia cells.
*Overall GPA:*18.32/20
- 2009 – 2012 M.Sc. degree in Clinical Biochemistry, Tabriz University of Medical Sciences, Iran
Thesis: Study of PPAR α and ERK-MAPK signaling pathway effect on the Δ 6- and Δ 9-desaturase genes expression and fatty acid composition of HepG2 cell line
*Overall GPA:*18.58/20
- 2004-2009 B.Sc. degree in Biology, University of Tabriz, Iran
*Overall GPA:*15.58/20

KEY RESPONSIBILITIES

- 2022- now Associate professor at Tabriz University of Medical Sciences (TUMS)
- 2016 - 2022 Assistant professor at Tabriz University of Medical Sciences (TUMS)
- 2107 - now Director of Clinical Laboratory at Shohada Hospital, Tabriz, Iran
- 2018 - now Head of Clinical Research and Development Unit of Shohada Hospital
- 2018 - 2020 Technical Director of Clinical Laboratory at Razi Hospital, Tabriz, Iran
- 2015 - 2017 Head of Molecular Targeted Therapy Research Group, TUMS

HONORS AND AWARDS

- 2022 One of World's Top 1% Higley Cited Researchers according to Essential Science Indicators and Clarivate Analytics
- 2022 The Best Medical Researcher in East Azerbaijan Province, Iran
- 2022 First-Ranked among 409 biochemists that work in Iranian medical universities
- 2021 One of World's Top 2% Higley Cited Researchers according to Essential Science Indicators and Clarivate Analytics
- 2020 One of World's Top 2% Higley Cited Researchers according to Essential Science Indicators and Clarivate Analytics

2019	The Best Young Researcher in Iran, honored by Ministry of Health and Medical Education
2019	As the head of the Clinical Research Development Unit, I was able to bring this unit to the Second Place between all research unit in the country and first rank in the university among various units
2018	2nd-ranked Best Researcher in Tabriz University of Medical Sciences (TUMS)
2018	As an instructor of the Olympiad in basic sciences, I helped the team to win 14 gold, silver and bronze medals in country
2017	1 st Rank Best Researcher in TUMS
2016	1 st Rank Best Researcher in TUMS
2015	Selected as top Young Researcher by Biochemical Society of Iran
2015	Selected as Top Young Researcher of Iranian Society of Laboratians in country
2015	The best PhD thesis of TUMS
2014	Top PhD student of Country, honored by the President of Iran
2014	Selected as Top Talented Student Researcher in Ministry of Health and Medical Education
2013- now	Member of Iran's National Elites Foundation

ADMINISTRATIVE EXPERIENCES

2020 - now	Founding member, Molecular Medicine Research Center, TUMS
2019 - now	Member of the Research Council Board, Molecular Medicine Research, TUMS
2019 - now	Secretary of Operation Committee of Laboratory Services, TUMS
2018 - now	Member of Accreditation Committee of Education and Research of Shohada Hospital
2017 - now	Member of the Research Council Board, Immunology Research Center, TUMS
2018 - 2022	Member of executive team, Iran Northwestern Central Biobank
2018 - 2019	Member of the Research Council Board, Aging Research Institute
2018 - 2019	Member of the Research Council Board, Stem Cells Research Center, TUMS
2017 - 2020	Counseling professor to support talented and brilliant students

PROFISSIONAL ASSOSTIONS

- Biochemical Society of Iran
- Member of Iran's National Elites Foundation

- Iranian Society of Physiology and Pharmacology

MEMBER of EDITORIAL BOARD

- 2022 Invited as Guest Editor *Genes* (Impact Factor: 4.1); Published by MDPI
 Link: https://www.mdpi.com/journal/genes/special_issue_flyer_pdf/05Y098QAG8/web
- 2021 Invited as Guest Editor, *Chemical Biology and Drug Design* (Impact Factor: 2.8)
 Link: <https://onlinelibrary.wiley.com/page/journal/17470285/homepage/cfp#rna>
- 2021 Invited as Guest Editor, *Biochimie*; (Impact Factor: 4.08); Published by Elsevier
 Link: <https://www.sciencedirect.com/science/article/abs/pii/S030090842200267X>

JOURNAL REVIEWER

Reviewing more than 120 papers for ISI peer reviewed journals for example:

Biomaterials (IF: 15.3), *Redox Biology* (IF:11.8), *Journal of Control Release* (IF:11.4),
Biomedicine & Pharmacotherapy (IF:6.5), , *European Journal of Pharmacology* (IF:4.4),
Biochimie (IF: 4.2), *Critical Reviews in Food Science and Nutrition* (IF: 11.2), *Journal of Cellular Physiology*(IF:6.7), *DNA Repair* (IF:4.2), *Experimental Cell Research* (IF:3.9),
Chemico-Biological Interactions (IF:5.1), *Gene* (IF:5.2).

PUBLICATIONS OVERVIEW

- **Papers:** 230
- **Citations:** 20,880
- **H-index:** 52
- **i10-index:**164
- **Corresponding-Author Papers:** 113
- **First-Author Papers:** 13
- **Citations per Papers:** 90.74

INTERNATIONAL COLLABORATIONS

International Papers: 47

- United State of America: 15
- Canada: 9
- Australia: 4
- Sweden: 3
- Spain: 5
- China: 9
- Brazil: 5
- Turkey: 4
- Germany: 3
- Azerbaijan: 6

SOME of PUBLICATIONS

1. M Vaghari-Tabari, N Targhazeh, S Moein, D Qujeq, F Alemi, M Majidina, **B Yousefi***. From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs? *Cancer Cell International* 22 (1), 1-21. 2022.
2. Homayoonfal M, Asemi Z, **Yousefi B***. Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. *Cell Mol Biol Lett*. Mar 2;27(1):21. 2022.
3. Sadoughi F, Mirsafaei L, Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, Montazer M, Hosseinpour M, **Yousefi B**. The role of DNA damage response in chemo-and radio- resistance of cancer cells: Can DDR inhibitors solve the problem? *DNA repair*. 2021;101:103074.
4. Sadoughi F, Maleki Dana P, Asemi Z, **Yousefi B**. Targeting microRNAs by curcumin: implication for cancer therapy. *Critical Reviews in Food Science and Nutrition*. 2021;1-12.
5. Mohammad Mirza- Aghazadeh- Attari, Ainaz Mihanfar, **Bahman Yousefi** and Maryam Majidinia. Nanotechnology- based advances in the efficient delivery of melatonin. *Cancer Cell International* 2022 22:43.
6. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. Maleki Dana P, Sadoughi F, Asemi Z, **Yousefi B**. *Cell Mol Biol Lett*. 2022 Jan 3;27(1):1
7. Valizadeh A, Asghari S, Mansouri P, Alemi F, Majidinia M, Mahmoodpoor A, **Yousefi B**. The Roles of Signaling Pathways in Cardiac Regeneration. *Current medicinal chemistry*. 2022.
8. A Karimian, M Majidinia, A Moliani, F Alemi, Z Asemi, **B Yousefi***, et al. The modulatory effects of two bioflavonoids, quercetin and thymoquinone on the expression levels of DNA damage and repair genes in human breast, lung and prostate cancer cell lines. *Pathology-Research and Practice*, 154143.
9. F Malakoti, E Mohammadi, M Akbari Oryani, D Shanebandi, **B Yousefi***, et al. Polyphenols and

inflammatory bowel disease: Natural products with therapeutic effects? *Critical Reviews in Food Science and Nutrition*, 1-17. 2022.

10. **Yousefi B**, Kokhaei P, Mehranfar F, Bahar A, Abdolshahi A, Emadi A, Eslami M. CircRNAs: A novel strategy in diagnosis and treatment of thyroid cancer
11. Vaghari-Tabari M, Mohammadzadeh I, Qujeq D, Majidinia M, Alemi F, Younesi S, Mahmoodpoor A, Maleki M, **Yousefi B***, Asemi Z. Vitamin D in respiratory viral infections: a key immune modulator? *Critical Reviews in Food Science and Nutrition*. 2021;1-16.
12. Targhazeh N, **Yousefi B**, Asghari S, Mohammadnejhad R, Mansouri P, Valizadeh A. MiR- 622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer. *Andrologia*. 2021;53(9):e14174.
13. Yousefi L, Osquee HO, Ghotaslou R, Rezaee MA, Pirzadeh T, Sadeghi J, Hemmati F, **Yousefi B**, Moaddab SY, Yousefi M. Dysregulation of lncRNA in Helicobacter pylori- Infected Gastric Cancer Cells. *BioMed Research International*. 2021;2021.
14. Maleki Dana P, Sadoughi F, Mirzaei H, Asemi Z, **Yousefi B***. DNA damage response and repair in the development and treatment of brain tumors. *Eur J Pharmacol*. 2022. Apr 14;924:174957.
15. Valizadeh A, Sayadmanesh A, Asemi Z, Alemi F, Mahmoodpoor A, **Yousefi B**. Regulatory Roles of the Notch Signaling Pathway in Liver Repair and Regeneration: A Novel Therapeutic Target. *Current Medicinal Chemistry*. 2021;28(41):8608-26.
16. Valizadeh A, Asghari S, Bastani S, Sarvari R, Keyhanvar N, Razin SJ, Khiabani AY, **Yousefi B**, Yousefi M, Shoaee-Hassani A. Will stem cells from fat and growth factors from blood bring new hope to female patients with reproductive disorders? *Reproductive Biology*. 2021;21(2):100472.
17. R Pourakbari, M Yousefi, B Khalilzadeh, MH Irani-nezhad, A Khataee, Aghebati-Maleki, Alireza Soleimanian, Amin Kamrani, Forough Chakari-Khiavi, Abolhasan, Motallebnezhad, Farhad Jadidi-Niaragh, **B Yousefi**, Samadi Kafil, Hojjat-Farsangi, Rashidi. Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform. *Cancer Nanotechnology* 13 (1), 1-17
18. **Yousefi B**, F Sadoughi, Z Asemi, MA Mansournia, J Hallajzadeh. Novel Perspectives for the Diagnosis and Treatment of Gynecological Cancers using Dysregulation of PIWI Protein and PiRNAs as Biomarkers. *Curr Med Chem*. 2023. PMID: 36786140
19. N Targhazeh, KJ Hutt, AL Winship, R Reiter, **B Yousefi***. Melatonin as an oncostatic agent: Review of the modulation of tumor microenvironment and overcoming multidrug resistance. *Biochimie*. 2022.
20. F Malakoti, E Mohammadi, M Akbari Oryani, D Shanebandi, **B Yousefi***. Polyphenols target miRNAs as a therapeutic strategy for diabetic complications. *Critical Reviews in Food Science and Nutrition*, 1-17. 2022.
21. Sadoughi F, Hallajzadeh J, Mirsafaei L, Asemi Z, Zahedi M, Mansournia MA, **Yousefi B**. Cardiac fibrosis and curcumin: a novel perspective on this natural medicine. *Molecular Biology Reports*. 2021;48(11):7597-608.
22. Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Nanocellulose-based delivery systems and cervical cancer: Review of the literature. *Current pharmaceutical design*. 2021;27(46):4707-15.
23. Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, Alemi F, **Yousefi B**. Signaling pathways involved in cell cycle arrest during the DNA breaks. *DNA repair*. 2021;98:103047.

24. Sadoughi F, Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Coagulopathy: Another side effect of coronavirus infection. *Journal of cardiovascular and thoracic research*. 2021;13(1):15.
25. Sadoughi F, Dana PM, Asemi Z, **Yousefi B**. DNA damage response and repair in osteosarcoma: defects, regulation and therapeutic implications. *DNA repair*. 2021;102:103105.
26. Rameshknia V, Movahhedi M, Akhavan A, Majidinia M, **Yousefi B**. Effect of Melatonin on Reversing Multidrug Resistance by Targeting Phosphatase and Tensin Homolog in Leukemia Cancer Cells. *Iranian Red Crescent Medical Journal*. 2021;23(7).
27. Pazhooh RD, Farnood PR, Asemi Z, Mirsafaei L, **Yousefi B**, Mirzaei H. mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy. *DNA repair*. 2021;104:103142.
28. Ozma MA, Khodadadi E, Pakdel F, Kamounah FS, Yousefi M, **Yousefi B**, Asgharzadeh M, Ganbarov K, Kafil HS. Baicalin, a natural antimicrobial and anti-biofilm agent. *Journal of Herbal Medicine*. 2021;27:100432.
29. Ni G, **Yousefi B**, Qujeq D, Marjani A, Asadi J, Wang Z, Mir SM. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells. *Materials Science and Engineering: C*. 2021;119:111554.
30. Mohammadi E, Sadoughi F, Younesi S, Karimian A, Asemi Z, Farsad-Akhtar N, Jahanbakhshi F, Jamilian H, **Yousefi B**. The molecular mechanism of nuclear signaling for degradation of cytoplasmic DNA: Importance in DNA damage response and cancer. *DNA repair*. 2021;103:103115.
31. Mirza-Aghazadeh-Attari M, Recio MJ, Darband SG, Kaviani M, Safa A, Mihanfar A, Sadighparvar S, Karimian A, Alemi F, Majidinia M. DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition. *DNA repair*. 2021;98:103032.
32. Mihanfar A, **Yousefi B**, Darband SG, Sadighparvar S, Kaviani M, Majidinia M. Melatonin increases 5-fluorouracil-mediated apoptosis of colorectal cancer cells through enhancing oxidative stress and downregulating survivin and XIAP. *BioImpacts: BI*. 2021;11(4):253.
33. Mihanfar A, Targhazeh N, Sadighparvar S, Darband SG, Majidinia M, **Yousefi B**. Doxorubicin loaded magnetism nanoparticles based on cyclodextrin dendritic-graphene oxide inhibited MCF-7 cell proliferation. *Biomolecular Concepts*. 2021;12(1):8-15.
34. Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, **Yousefi B**, Majidinia M. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: Possible mechanistic view. *Chemico-Biological Interactions*. 2021;337:109337.
35. Maleki M, Khelghati N, Alemi F, Younesi S, Asemi Z, Abolhasan R, Bazdar M, Samadi-Kafil H, **Yousefi B**. Multiple interactions between melatonin and non-coding RNAs in cancer biology. *Chemical Biology & Drug Design*. 2021;98(3):323-40.
36. Maleki M, Golchin A, Javadi S, Khelghati N, Morovat P, Asemi Z, Alemi F, Vaghari-Tabari M, **Yousefi B**, Majidinia M. Role of exosomal miRNA in chemotherapy resistance of Colorectal cancer: A systematic review. *Chemical Biology & Drug Design*. 2021.
37. Maleki M, Golchin A, Alemi F, Younesi S, Asemi Z, Javadi S, Khiavi PA, Soleinmapour J, **Yousefi B**. Cytotoxicity and apoptosis of nanoparticles on osteosarcoma cells using doxorubicin and methotrexate: A systematic review. *European Journal of Pharmacology*. 2021;904:174131.
38. Maleki Dana P, Sadoughi F, Mansournia MA, Mirzaei H, Asemi Z, **Yousefi B**. Targeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases. *Biogerontology*. 2021;22(5):479-94.
39. Maleki Dana P, Sadoughi F, Asemi Z, **Yousefi B**. Anti-cancer properties of quercetin in osteosarcoma. *Cancer Cell International*. 2021;21(1):1-9.
40. Malakoti F, Alemi F, Younesi S, Majidinia M, **Yousefi B**, Morovat P, Khelghati N, Maleki M, Karimian A, Asemi Z. The cross-talk between signaling pathways, noncoding RNAs and DNA

- damage response: Emerging players in cancer progression. *DNA repair*. 2021;98:103036.
41. Malakoti F, Alemi F, Karimzadeh H, Asemi Z, Asadi M, Ghobadi H, Soleimanpour J, **Yousefi B**. Long noncoding RNA-miRNA-mRNA axes multiple roles in osteosarcoma. *Gene Reports*. 2021;23:101090.
 42. Khodadadi E, Fahmideh L, Khodadadi E, Dao S, Yousefi M, Taghizadeh S, Asgharzadeh M, **Yousefi B**, Kafil HS. Current advances in DNA methylation analysis methods. *BioMed Research International*. 2021;2021.
 43. Khelghati N, Soleimanpour Mokhtarvand J, Mir M, Alemi F, Asemi Z, Sadeghpour A, Maleki M, Samadi Kafil H, Jadidi-niaragh F, Majidinia M. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. *Chemical Biology & Drug Design*. 2021;97(4):997-1015.
 44. Kamrani A, Soltani-Zangbar MS, Shiri S, Yousefzadeh Y, Pourakbari R, Aghebati-Maleki L, Mehdizadeh A, Danaei S, Jadidi-Niaragh F, **Yousefi B**. TIGIT and CD155 as Immune- Modulator Receptor and Ligand on CD4+ T cells in Preeclampsia Patients. *Immunological Investigations*. 2021:1-16.
 45. Jahanbakhshi F, Dana PM, Badehnoosh B, **Yousefi B**, Mansournia MA, Jahanshahi M, Asemi Z, Halajzadeh J. Curcumin anti-tumor effects on endometrial cancer with focus on its molecular targets. *Cancer Cell International*. 2021;21(1):1-7.
 46. Hosseini F, Alemi F, Malakoti F, Mahmoodpoor A, Younesi S, **Yousefi B**, Asemi Z. Targeting Wnt/ β -catenin signaling by microRNAs as a therapeutic approach in chemoresistant osteosarcoma. *Biochemical Pharmacology*. 2021;193:114758.
 47. Homayoonfal M, Asemi Z, **Yousefi B**. Targeting long non coding RNA by natural products: Implications for cancer therapy. *Critical Reviews in Food Science and Nutrition*. 2021:1-29.
 48. Homayoonfal M, Asemi Z, **Yousefi B**. Targeting microRNAs with thymoquinone: a new approach for cancer therapy. *Cellular & Molecular Biology Letters*. 2021;26(1):1-22.
 49. Eslahi M, Sadoughi F, Asemi Z, **Yousefi B**, Mansournia MA, Hallajzadeh J. Chitosan and Wnt/ β -catenin Signaling Pathways in Different Cancers. *Combinatorial Chemistry & High Throughput Screening*. 2021;24(9):1323-31.
 50. Eslahi M, Maleki Dana P, Sadoughi F, Hallajzadeh J, Asemi Z, Sharifi M, Mansournia MA, **Yousefi B**. The Effects of Sterol-Related Signaling Pathways on Glioma. *Nutrition and Cancer*. 2021:1-11.
 51. Eslahi M, Dana PM, Asemi Z, Hallajzadeh J, Mansournia MA, **Yousefi B**. The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment. *International journal of biological macromolecules*. 2021;168:124-9.
 52. Farnood PR, Pazhooh RD, Asemi Z, **Yousefi B**. DNA damage response and repair in pancreatic cancer development and therapy. *DNA repair*. 2021;103:103116.
 53. Digesaraei TY, Tehrani SS, Abolghasemi M, Karimian A, Valizadeh A, Targhazeh N, Bastami M, Jadidi-Niaragh F, Yousefi M, Kafil HS. Critical roles of long noncoding RNAs in breast cancer (vol 235, pg 5059, 2020). *JOURNAL OF CELLULAR PHYSIOLOGY*. 2021.
 54. Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Chitosan applications in studying and managing osteosarcoma. *International journal of biological macromolecules*. 2021;169:321-9.
 55. PM Dana, F Sadoughi, RJ Reiter, **B Yousefi**, Z Asemi Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review. *Mini Reviews in Medicinal Chemistry* 23 (3), 290-297
 56. Alemi F, Raei Sadigh A, Malakoti F, Elhaei Y, Ghaffari SH, Maleki M, Asemi Z, **Yousefi B**, Targhazeh N, Majidinia M. Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk. *Journal of Cellular Physiology*. 2021.

57. Akbarzadeh M, Mihanfar A, Akbarzadeh S, **Yousefi B**, Majidinia M. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. *Life Sciences*. 2021;285:119984.
58. **Yousefi B**, Sanaie S, Ghamari AA, Soleimanpour H, Karimian A, Mahmoodpoor A. Red cell distribution width as a novel prognostic marker in multiple clinical studies. *Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine*. 2020;24(1):49.
59. Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F, Mohamadzadeh R, Targhazeh N, Safa A, **Yousefi B**. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. *Life Sciences*. 2020;259:118255.
60. Talebian S, Daghigh H, **Yousefi B**, Özkul Y, Ilkhani K, Seif F, Alivand MR. The role of epigenetics and non-coding RNAs in autophagy: A new perspective for thorough understanding. *Mechanisms of ageing and development*. 2020;190:111309.
61. Taghavipour M, Sadoughi F, Mirzaei H, **Yousefi B**, Moazzami B, Chaichian S, Mansournia MA, Asemi Z. Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. *Cell & Bioscience*. 2020;10(1):1-9.
62. Suntar I, Sureda A, Belwal T, Silva AS, Vacca RA, Tewari D, Sobarzo-Sánchez E, Nabavi SF, Shirooie S, Dehpour AR. Natural products, PGC-1 α , and Duchenne muscular dystrophy. *Acta Pharmaceutica Sinica B*. 2020;10(5):734-45.
63. Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, Safa A, Yosefi B. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. *European Journal of Pharmacology*. 2020;880:173138.
64. Shafabakhsh R, **Yousefi B**, Asemi Z, Nikfar B, Mansournia MA, Hallajzadeh J. Chitosan: A compound for drug delivery system in gastric cancer-a review. *Carbohydrate Polymers*. 2020;242:116403.
65. Sanches-Silva A, Testai L, Nabavi SF, Battino M, Devi KP, Tejada S, Sureda A, Xu S, **Yousefi B**, Majidinia M. Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway. *Pharmacological research*. 2020;152:104626.
66. Salamati A, Majidinia M, Asemi Z, Sadeghpour A, Oskoi MA, Shanebandi D, Alemi F, Mohammadi E, Karimian A, Targhazeh N. Modulation of telomerase expression and function by miRNAs: Anti-cancer potential. *Life Sciences*. 2020;259:118387.
67. Sadighparvar S, Targhazeh N, Karimian A, Shafiei-Irannejad V, Farsad-Akhtar N, Rafieian S, Salamati A, Bastami M, Kafil HS, Yousefi M. Downregulation of microRNA-214 and PTEN in tissue samples of patients with breast cancer. *Meta Gene*. 2020;24:100668.
68. Sadighparvar S, Darband SG, **Yousefi B**, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, Babaei G, Mobaraki K, Majidinia M. Combination of quercetin and exercise training attenuates depression in rats with 1, 2-dimethylhydrazine-induced colorectal cancer: Possible involvement of inflammation and BDNF signalling. *Experimental physiology*. 2020;105(9):1598-609.
69. Reiter R, Hallajzadeh J, Asemi Z, Mansournia M, **Yousefi B**. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. *IUBMB Life*. 2020.
70. Rahimi M, Noruzi EB, Sheykhsaran E, Ebadi B, Kariminezhad Z, Molapourast M, Mehrabani MG, Mehramouz B, Yousefi M, Ahmadi R. Carbohydrate polymer-based silver nanocomposites: Recent progress in the antimicrobial wound dressings. *Carbohydrate polymers*. 2020;231:115696.
71. Pishgahi A, Abolhasan R, Danaii S, Amanifar B, Soltani-Zangbar MS, Zamani M, Kamrani A, Ghorbani F, Mehdizadeh A, Kafil HS. Immunological and oxidative stress biomarkers in ankylosing spondylitis patients with or without metabolic syndrome. *Cytokine*. 2020;128:155002.
72. Oskoi MA, Khatami N, Majidinia M, Rezazadeh M-A, Mir SM, Sadeghpour A, **Yousefi B**. Serum

- level of melatonin in patients with osteoarthritis and its relation with 8-hydroxy-2- deoxyguanosine and vitamin D. *Journal of Research in Clinical Medicine*. 2020;8(1):34-.
73. Malakoti, Majidinia, Ahmadi, **Yousefi B**, Shanebandi. Quercetin Augments Cisplatin-Induced Apoptosis, DNA Damage Response, and MiR-22 Expression While It Prevents DNA Repair in Osteosarcoma Drug Res (Stuttg) 2022; 72(07): 378-384.
 74. Mirza-Aghazadeh-Attari M, Reiter RJ, Rikhtegar R, Jalili J, Hajalioghli P, Mihanfar A, Majidinia M, **Yousefi B**. Melatonin: An atypical hormone with major functions in the regulation of angiogenesis. *IUBMB life*. 2020;72(8):1560-84.
 75. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Mostavafi S, Mihanfar A, Ghazizadeh S, Sadighparvar S, Gholamzadeh S, Majidinia M, **Yousefi B**. Melatonin: An important anticancer agent in colorectal cancer. *Journal of cellular physiology*. 2020;235(2):804-17.
 76. Mirza-Aghazadeh-Attari M, Ekrami EM, Aghdas SAM, Mihanfar A, Hallaj S, **Yousefi B**, Safa A, Majidinia M. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer therapy. *Life sciences*. 2020;255:117481.
 77. Mir SM, **Yousefi B**, Marjani A, Rahimi M, Qujeq D. The sensitization of melatonin in osteosarcoma cells by suppression of anti-apoptotic proteins. *Pharmaceutical Sciences*. 2020;26(2):159-64.
 78. Maleki M, Zarezadeh R, Nouri M, Sadigh AR, Pouremamali F, Asemi Z, Kafil HS, Alemi F, **Yousefi B**. Graphene Oxide: A Promising Material for Regenerative Medicine and Tissue Engineering. *Biomolecular Concepts*. 2020;11(1):182-200.
 79. Maleki M, Khelghati N, Alemi F, Bazdar M, Asemi Z, Majidinia M, Sadeghpour A, Mahmoodpour A, Jadidi-Niaragh F, Targhazeh N. Stabilization of telomere by the antioxidant property of polyphenols: Anti-aging potential. *Life Sciences*. 2020;259:118341.
 80. Maleki Dana P, Reiter RJ, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. *Iubmb Life*. 2020;72(11):2355-65.
 81. Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, **Yousefi B**. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. *IUBMB life*. 2020;72(5):855-71.
 82. Majidinia M, Mir SM, Mirza-Aghazadeh-Attari M, Asghari R, Kafil HS, Safa A, Mahmoodpour A, **Yousefi B**. MicroRNAs, DNA damage response and ageing. *Biogerontology*. 2020;21(3):275-91.
 83. Majidinia M, Karimian A, Alemi F, **Yousefi B**, Safa A. Targeting miRNAs by polyphenols: Novel therapeutic strategy for aging. *Biochemical pharmacology*. 2020;173:113688.
 84. Leylabadlo HE, Ghotaslou R, Feizabadi MM, Farajnia S, Moaddab SY, Ganbarov K, Khodadadi E, Tanomand A, Sheykhsaran E, **Yousefi B**. The critical role of Faecalibacterium prausnitzii in human health: An overview. *Microbial pathogenesis*. 2020;149:104344.
 85. Khodadadi E, Zeinalzadeh E, Taghizadeh S, Mehramouz B, Kamounah FS, Khodadadi E, Ganbarov K, **Yousefi B**, Bastami M, Kafil HS. Proteomic applications in antimicrobial resistance and clinical microbiology studies. *Infection and Drug Resistance*. 2020;13:1785.
 86. Khelghati N, Rasmi Y, Farahmandan N, Sadeghpour A, Mir SM, Karimian A, **Yousefi B**. Hyperbranched polyglycerol β -cyclodextrin as magnetic platform for optimization of doxorubicin cytotoxic effects on Saos-2 bone cancerous cell line. *Journal of Drug Delivery Science and Technology*. 2020;57:101741.
 87. Karimian A, Gorjizadeh N, Alemi F, Asemi Z, Azizian K, Soleimanpour J, Malakouti F, Targhazeh N, Majidinia M, **Yousefi B**. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases. *Life Sciences*. 2020;259:118165.
 88. Karimi N, Jabbari V, Nazemi A, Ganbarov K, Karimi N, Tanomand A, Karimi S, Abbasi A, **Yousefi**

- B**, Khodadadi E. Thymol, cardamom and Lactobacillus plantarum nanoparticles as a functional candy with high protection against Streptococcus mutans and tooth decay. *Microbial pathogenesis*. 2020;148:104481.
89. Jahanshahi M, Dana PM, Badehnoosh B, Asemi Z, Hallajzadeh J, Mansournia MA, **Yousefi B**, Moazzami B, Chaichian S. Anti-tumor activities of probiotics in cervical cancer. *Journal of ovarian research*. 2020;13(1):1-11.
 90. Iranparast S, Tayebi S, Ahmadpour F, **Yousefi B**. Tumor-Induced metabolism and T cells located in tumor environment. *Current Cancer Drug Targets*. 2020;20(10):741-56.
 91. Hashemi V, Maleki LA, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, Yousefi M, **Yousefi B**, Jadidi-Niaragh F. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. *International immunopharmacology*. 2020;78:106087.
 92. Hashemi V, Ahmadi A, Malakotikhah F, Chaleshtari MG, Moornani MB, Masjedi A, Sojoodi M, Atyabi F, Nikkhoo A, Rostami N. Silencing of p68 and STAT3 synergistically diminishes cancer progression. *Life Sciences*. 2020;249:117499.
 93. Hallajzadeh J, Maleki Dana P, Mobini M, Asemi Z, Mansournia MA, Sharifi M, **Yousefi B**. Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer. *Medical Oncology*. 2020;37(6):1-9.
 94. Hallajzadeh J, Amirani E, Mirzaei H, Shafabakhsh R, Mirhashemi SM, Sharifi M, **Yousefi B**, Mansournia MA, Asemi Z. Circular RNAs: new genetic tools in melanoma. *Biomarkers in medicine*. 2020;14(7):563-71.
 95. Halajzadeh J, Dana PM, Asemi Z, Mansournia MA, **Yousefi B**. An insight into the roles of piRNAs and PIWI proteins in the diagnosis and pathogenesis of oral, esophageal, and gastric cancer. *Pathology-Research and Practice*. 2020;216(10):153112.
 96. Haiaty S, Rashidi MR, Akbarzadeh M, Maroufi NF, **Yousefi B**, Nouri M. Targeting vasculogenic mimicry by phytochemicals: a potential opportunity for cancer therapy. *IUBMB life*. 2020;72(5):825-41.
 97. Gholizadeh P, Köse Ş, Dao S, Ganbarov K, Tanomand A, Dal T, Aghazadeh M, Ghotaslou R, Rezaee MA, **Yousefi B**. How CRISPR-Cas system could be used to combat antimicrobial resistance. *Infection and drug resistance*. 2020;13:1111.
 98. Fakhri E, Eslami H, Maroufi P, Pakdel F, Taghizadeh S, Ganbarov K, Yousefi M, Tanomand A, **Yousefi B**, Mahmoudi S. Chitosan biomaterials application in dentistry. *International journal of biological macromolecules*. 2020;162:956-74.
 99. Ezzati M, **Yousefi B**, Velaei K, Safa A. A review on anti-cancer properties of Quercetin in breast cancer. *Life Sciences*. 2020;248:117463.
 100. Darband SG, Sadighparvar S, **Yousefi B**, Kaviani M, Mobaraki K, Majidinia M. Combination of exercise training and L-arginine reverses aging process through suppression of oxidative stress, inflammation, and apoptosis in the rat heart. *Pflügers Archiv-European Journal of Physiology*. 2020;472(2):169-78.
 101. Darband SG, Sadighparvar S, **Yousefi B**, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, Rahimi Y, Mobaraki K, Majidinia M. Quercetin attenuated oxidative DNA damage through NRF2 signaling pathway in rats with DMH induced colon carcinogenesis. *Life Sciences*. 2020;253:117584.
 102. Danaii S, Abolhasani R, Soltani-Zangbar MS, Zamani M, Mehdizadeh A, Amanifar B, **Yousefi B**, Nazari M, Poulak T, Hajialiloo M. Immunological and oxidative stress biomarkers in Ankylosing spondylitis patients. *Gene Reports*. 2020;18:100574.
 103. Dana PM, Taghavipour M, Mirzaei H, **Yousefi B**, Moazzami B, Chaichian S, Asemi Z. Circular RNA as a potential diagnostic and/or therapeutic target for endometriosis. *Biomarkers in*

Medicine. 2020;14(13):1277-87.

104. Dana PM, Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**, Momen-Heravi M. An insight into the sex differences in COVID-19 patients: what are the possible causes? *Prehospital and disaster medicine*. 2020;35(4):438-41.
105. Bazavar M, Fazli J, Valizadeh A, Ma B, Mohammadi E, Asemi Z, Alemi F, Maleki M, Xing S, **Yousefi B**. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. *Pathology-Research and Practice*. 2020;216(11):153176.
106. Amirani E, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. *International journal of biological macromolecules*. 2020;164:456-67.
107. Alemi F, Zarezadeh R, Sadigh AR, Hamishehkar H, Rahimi M, Majidinia M, Asemi Z, Ebrahimi-Kalan A, **Yousefi B**, Rashtchizadeh N. Graphene oxide and reduced graphene oxide: Efficient cargo platforms for cancer theranostics. *Journal of Drug Delivery Science and Technology*. 2020;60:101974.
108. Ahmadi Y, Mahmoudi N, **Yousefi B**, Karimian A. The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; new functions for statins. *Pharmacological Research*. 2020;152:104621.
109. Ahmadi D, Zarei M, Rahimi M, Khazaie M, Asemi Z, Mir SM, Sadeghpour A, Karimian A, Alemi F, Rahmati-Yamchi M. Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. *Journal of Drug Delivery Science and Technology*. 2020;57:101584.
110. Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpour A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M. Critical roles of long noncoding RNAs in breast cancer. *Journal of cellular physiology*. 2020;235(6):5059-71.
111. Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpour A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M. MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. *Journal of cellular physiology*. 2020;235(6):5008-29.
112. Abdi SN, Ghotaslou R, Asgharzadeh M, Mehramouz B, Hasani A, Baghi HB, Tanomand A, Narenji H, **Yousefi B**, Gholizadeh P. AdeB efflux pump gene knockdown by mRNA mediated peptide nucleic acid in multidrug resistance *Acinetobacter baumannii*. *Microbial pathogenesis*. 2020;139:103825.
113. **Yousefi B**, Mohammadlou M, Abdollahi M, Salek Farrokhi A, Karbalaei M, Keikha M, Kokhaei P, Valizadeh S, Rezaeiemanesh A, Arabkari V. Epigenetic changes in gastric cancer induction by *Helicobacter pylori*. *Journal of cellular physiology*. 2019;234(12):21770-84.
114. Valizadeh A, Majidinia M, Samadi-Kafil H, Yousefi M, **Yousefi B**. The roles of signaling pathways in liver repair and regeneration. *Journal of Cellular Physiology*. 2019;234(9):14966-74.
115. Vahed SZ, Aghaee-Bakhtiari SH, Daraei A, Saadatian Z, Kafil HS, **Yousefi B**, Eyvazi S, Khaheshi I, Parsa SA, Moravej A. Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis. *Gene*. 2019;698:170-8.
116. Alemi F, Malakoti F, Vaghari-Tabari M, Soleimanpour J, Shabestani N, Sadigh AR, Khelghati N, Asemi Z, Ahmadi Y, **Yousefi B***. DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. *J Cell Physiol*. 2022 Apr 5. doi: 10.1002/jcp.30721. 2022.
117. Tabari FS, Karimian A, Parsian H, Rameshknia V, Mahmoodpour A, Majidinia M, Maniati M, **Yousefi B**. The roles of FGF21 in atherosclerosis pathogenesis. *Reviews in Endocrine and Metabolic*

Disorders. 2019;20(1):103-14.

118. Shafiei-Irannejad V, Rahimi M, Zarei M, Dinparast-Isaleh R, Bahrambeigi S, Alihemmati A, Shojaei S, Ghasemi Z, **Yousefi B**. Polyelectrolyte carboxymethyl cellulose for enhanced delivery of doxorubicin in MCF7 breast cancer cells: Toxicological evaluations in mice model. *Pharmaceutical research.* 2019;36(5):1-17.
119. Saadatian Z, Nariman-Saleh-Fam Z, Bastami M, Mansoori Y, Khareshi I, Parsa SA, Daraei A, Vahed SZ, **Yousefi B**, Kafil HS. Dysregulated expression of STAT1, miR-150, and miR- 223 in peripheral blood mononuclear cells of coronary artery disease patients with significant or insignificant stenosis. *Journal of cellular biochemistry.* 2019;120(12):19810-24.
120. Rostami N, Nikkhoo A, Ajjoolabady A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, **Yousefi B**, Yousefi M, Jadidi-Niaragh F. S1PR1 as a novel promising therapeutic target in cancer therapy. *Molecular Diagnosis & Therapy.* 2019;23(4):467-87.
121. Pourakbari, Parhizkar, Soltani-Zangbar, Samadi, Zamani, Aghebati-Maleki, Motavalli, Mahmoodpoor, Jadidi-Niaragh, **Yousefi B**, Samadi Kafil, Hojjat-Farsangi, Danaii, Yousefi. Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women *Reprod Sci.* 2022 Sep 26.
122. doi: 10.1007/s43032-022-01059-x. Ranjbar R, Karimian A, Aghaie Fard A, Tourani M, Majidinia M, Jadidi-Niaragh F, **Yousefi B**. The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis. *Journal of cellular physiology.* 2019;234(4):3216-30.
123. Rahimi M, Karimian R, Noruzi EB, Ganbarov K, Zarei M, Kamounah FS, **Yousefi B**, Bastami M, Yousefi M, Kafil HS. Needle-shaped amphoteric calix [4] arene as a magnetic nanocarrier for simultaneous delivery of anticancer drugs to the breast cancer cells. *International journal of nanomedicine.* 2019;14:2619.
124. Nikkhoo A, Rostami N, Hojjat-Farsangi M, Azizi G, **Yousefi B**, Ghalamfarsa G, Jadidi-Niaragh F. Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. *Journal of Cellular Biochemistry.* 2019;120(6):9300-14.
125. Nabavi SM, Ahmed T, Nawaz M, Devi KP, Balan DJ, Pittalà V, Argüelles-Castilla S, Testai L, Khan H, Sureda A. Targeting STATs in neuroinflammation: The road less traveled! *Pharmacological research.* 2019;141:73-84.
126. MOHAMMADZADEH R, BARADARAN B, **YOUSEFI B**, VALIZADEH H, ZAKERI-MILANI P. Attenuation of intestinal efflux pump thru polymers and preservatives. *J Res Pharm.* 2019;23(4):632-41.
127. Mohammadzadeh A, Mirza-Aghazadeh-Attari M, Hallaj S, Saei AA, Alivand MR, Valizadeh A, **Yousefi B**, Majidinia M. Crosstalk between P53 and DNA damage response in ageing. *DNA repair.* 2019;80:8-15.
128. M Vaghari-Tabari, P Hassanpour, F Sadeghsoltani, F Malakoti, F Alemi, **B Yousefi***. CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. *Cellular & Molecular Biology Letters* 27 (1), 1-29. 2022.
129. Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Kafil HS, **Yousefi B**, Majidinia M. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. *DNA repair.* 2019;80:59-84.
130. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, **Yousefi B**, Mihanfar A, Karimian A, Majidinia M. 53BP1: A key player of DNA damage response with critical functions in cancer. *DNA repair.* 2019;73:110-9.
131. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Adib A, Darband SG, Sadighparvar S, Mihanfar A, Majidinia M, **Yousefi B**. Melatonin-mediated regulation of autophagy: making sense of

- double-edged sword in cancer. *Journal of cellular physiology*. 2019;234(10):17011- 22.
132. Mihanfar A, Aghazadeh Attari J, Mohebbi I, Majidinia M, Kaviani M, Yousefi M, **Yousefi B**. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance. *Journal of Cellular Physiology*. 2019;234(4):3238-53.
 133. Mashayekhi S, **Yousefi B**, Tohidi E, Darband SG, Mirza-Aghazadeh-Attari M, Sadighparvar S, Kaviani M, Shafiei-Irannejad V, Kafil HS, Karimian A. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin- resistance leukemia cancer cells to treatment. *Journal of Cellular Biochemistry*. 2019;120(9):15719-29.
 134. Majidinia M, Bishayee A, **Yousefi B**. Polyphenols: Major regulators of key components of DNA damage response in cancer. *DNA repair*. 2019;82:102679.
 135. Koushaeian L, Ghorbani F, Ahmadi M, Eghbal-Fard S, Zamani M, Danaii S, **Yousefi B**, Jadidi-Niaragh F, Hamdi K, Yousefi M. The role of IL-10-producing B cells in repeated implantation failure patients with cellular immune abnormalities. *Immunology letters*. 2019;214:16-22.
 136. Karpishev V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, **Yousefi B**, Jadidi-Niaragh F. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. *Prostaglandins & other lipid mediators*. 2019;144:106338.
 137. Karimian A, Parsian H, Majidinia M, Rahimi M, Mir SM, Kafil HS, Shafiei-Irannejad V, Kheyrollah M, Ostadi H, **Yousefi B**. Nanocrystalline cellulose: Preparation, physicochemical properties, and applications in drug delivery systems. *International journal of biological macromolecules*. 2019;133:850-9.
 138. Karimian A, Mir SM, Parsian H, Refieyan S, Mirza-Aghazadeh-Attari M, **Yousefi B**, Majidinia M. Crosstalk between Phosphoinositide 3-kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer. *Journal of Cellular Biochemistry*. 2019;120(6):10248-72.
 139. Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, Yousefi M, Majidinia M, **Yousefi B**. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. *Journal of cellular physiology*. 2019;234(8):12267-77.
 140. Karimi N, Ghanbarzadeh B, Hajibonabi F, Hojabri Z, Ganbarov K, Kafil HS, Hamishehkar H, Yousefi M, Mokarram RR, Kamounah FS. Turmeric extract loaded nanoliposome as a potential antioxidant and antimicrobial nanocarrier for food applications. *Food Bioscience*. 2019;29:110-7.
 141. Jahanban-Esfahlan R, Seidi K, Majidinia M, Karimian A, **Yousefi B**, Nabavi SM, Astani A, Berindan-Neagoe I, Gulei D, Fallarino F. Toll-like receptors as novel therapeutic targets for herpes simplex virus infection. *Reviews in Medical Virology*. 2019;29(4):e2048.
 142. Jafarzadeh S, Ahmadi M, Dolati S, Aghebati-Maleki L, Eghbal-Fard S, Kamrani A, Behrad B, Roshangar L, Jadidi-Niaragh F, **Yousefi B**. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. *Journal of Cellular Biochemistry*. 2019;120(4):5424-34.
 143. Hasanifard L, Sheervalilou R, Majidinia M, **Yousefi B**. New insights into the roles and regulation of SphK2 as a therapeutic target in cancer chemoresistance. *Journal of cellular physiology*. 2019;234(6):8162-81.
 144. Gholizadeh P, Mahallei M, Pormohammad A, Varshochi M, Ganbarov K, Zeinalzadeh E, **Yousefi B**, Bastami M, Tanomand A, Mahmood SS. Microbial balance in the intestinal microbiota and its association with diabetes, obesity and allergic disease. *Microbial pathogenesis*. 2019;127:48-55.
 145. Eghbal-Fard S, Yousefi M, Heydarlou H, Ahmadi M, Taghavi S, Movasaghpour A, Jadidi-Niaragh F, **Yousefi B**, Dolati S, Hojjat-Farsangi M. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. *Journal of cellular physiology*. 2019;234(4):5106-16.
 146. Bastami M, Choupani J, Saadatian Z, Zununi Vahed S, Ouladsahebmadarek E, Mansoori Y,

- Daraei A, Samadi Kafil H, **Yousefi B**, Mahdipour M. Evidences from a systematic review and meta-analysis unveil the role of MiRNA polymorphisms in the predisposition to female neoplasms. *International Journal of Molecular Sciences*. 2019;20(20):5088.
147. Bahrambeigi S, **Yousefi B**, Rahimi M, Shafiei-Irannejad V. Metformin; an old antidiabetic drug with new potentials in bone disorders. *Biomedicine & Pharmacotherapy*. 2019;109:1593-601.
 148. Bahrambeigi S, Rahimi M, **Yousefi B**, Shafiei-Irannejad V. New potentials for 3- hydroxy-3-methyl- glutaryl- coenzymeA reductase inhibitors: Possible applications in retarding diabetic complications. *Journal of Cellular Physiology*. 2019;234(11):19393-405.
 149. Azizi R, Ahmadi M, Danaii S, Abdollahi-Fard S, Mosapour P, Eghbal-Fard S, Dolati S, Kamrani A, Rahnema B, Mehdizadeh A. Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio. *Journal of cellular physiology*. 2019;234(10):19039-47.
 150. Aryaeian N, Shahram F, Mahmoudi M, Tavakoli H, **Yousefi B**, Arablou T, Karegar SJ. The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active Rheumatoid Arthritis. *Gene*. 2019;698:179-85.
 151. Anvarnia A, Mohaddes-Gharamaleki F, Asadi M, Akbari M, **Yousefi B**, Shanehbandi D. Dysregulated microRNAs in colorectal carcinogenesis: new insight to cell survival and apoptosis regulation. *Journal of cellular physiology*. 2019;234(12):21683-93.
 152. Ahmadi R, Tanomand A, Kazeminava F, Kamounah FS, Ayaseh A, Ganbarov K, Yousefi M, Katourani A, **Yousefi B**, Kafil HS. Fabrication and characterization of a titanium dioxide (TiO₂) nanoparticles reinforced bio-nanocomposite containing Miswak (*Salvadora persica* L.) extract—the antimicrobial, thermo-physical and barrier properties. *International Journal of Nanomedicine*. 2019;14:3439.
 153. Mazandarani, Maleki Dana, Asemi, Hallajzadeh, Mansournia, **Yousefi B**. Effects of berberine on leukemia with a focus on its molecular targets. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)*, Volume 22, Number 15.
 154. Abdolmohammadi Vahid S, Ghaebi M, Ahmadi M, Nouri M, Danaei S, Aghebati-Maleki L, Mousavi Ardehaie R, **Yousefi B**, Hakimi P, Hojjat-Farsangi M. Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. *Journal of cellular physiology*. 2019;234(4):4924-33.
 155. Tehrani SS, Karimian A, Parsian H, Majidinia M, **Yousefi B**. Multiple functions of long non-coding RNAs in oxidative stress, DNA damage response and cancer progression. *Journal of cellular biochemistry*. 2018;119(1):223-36.
 156. Shafiei-Irannejad V, Samadi N, **Yousefi B**, Salehi R, Velaei K, Zarghami N. Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp- overexpressing MCF-7 cells. *Chemical biology & drug design*. 2018;91(1):269-76.
 157. Shafiei-Irannejad V, Samadi N, Salehi R, **Yousefi B**, Rahimi M, Akbarzadeh A, Zarghami N. Reversion of multidrug resistance by co-encapsulation of doxorubicin and metformin in poly (lactide-co-glycolide)-d- α -tocopheryl polyethylene glycol 1000 succinate nanoparticles. *Pharmaceutical research*. 2018;35(6):1-13.
 158. Alemi, Maleki, Mir, Ebrahimi-Kalan, Zarei, **Yousefi B**, Rashtchizadeh Synthesis, characterization, and evaluation of pH-sensitive doxorubicin-loaded functionalized graphene oxide in osteosarcoma cells. *BioImpacts*. 2018;233(10):6455-69. doi: 10.34172/bi.2022.23820
 159. Mirza-Aghazadeh-Attari M, Darband SG, Kaviani M, Mihanfar A, Attari JA, **Yousefi B**, Majidinia M. DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications. *DNA repair*. 2018;69:34-52.

160. Malakoti, Alemi, Jafari Yeganeh, Hosseini, Shabestani, Samemaleki, Maleki, Fathi Daneshvar, Montazer, **Yousefi B**. Long noncoding RNA SNHG7-miRNA-mRNA axes crosstalk with oncogenic signaling pathways in human cancers. *Chem Biol Drug Des*. 2022 Aug 22. doi: 10.1111/cbdd.14118.
161. Majidinia M, Reiter RJ, Shakouri SK, **Yousefi B**. The role of melatonin, a multitasking molecule, in retarding the processes of ageing. *Ageing research reviews*. 2018;47:198-213.
162. Majidinia M, Reiter RJ, Shakouri SK, Mohebbi I, Rastegar M, Kaviani M, Darband SG, Jahanban-Esfahlan R, Nabavi SM, **Yousefi B**. The multiple functions of melatonin in regenerative medicine. *Ageing research reviews*. 2018;45:33-52.
163. Ainaz Mihanfar, **Yousefi B**, Bitra Azizzadeh & Maryam Majidinia. Interactions of melatonin with various signaling pathways: implications for cancer therapy. *Cancer Cell International* volume 22, Article number: 420 (2022)
164. Majidinia M, Aghazadeh J, Jahanban-Esfahlan R, **Yousefi B**. The roles of Wnt/ β -catenin pathway in tissue development and regenerative medicine. *Journal of cellular physiology*. 2018;233(8):5598-612.
165. Khanzadeh T, Hagh MF, Talebi M, **Yousefi B**, Azimi A, Baradaran B. Investigation of BAX and BCL2 expression and apoptosis in a resveratrol-and prednisolone-treated human T- ALL cell line, CCRF-CEM. *Blood research*. 2018;53(1):53-60.
166. Jahanban-Esfahlan R, Seidi K, Banimohamad-Shotorbani B, Jahanban-Esfahlan A, **Yousefi B**. Combination of nanotechnology with vascular targeting agents for effective cancer therapy. *Journal of cellular physiology*. 2018;233(4):2982-92.
167. Jahanban-Esfahlan R, Mehrzadi S, Reiter RJ, Seidi K, Majidinia M, Baghi HB, Khatami N, **Yousefi B**, Sadeghpour A. Melatonin in regulation of inflammatory pathways in rheumatoid arthritis and osteoarthritis: involvement of circadian clock genes. *British journal of pharmacology*. 2018;175(16):3230-8.
168. Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, **Yousefi B**. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. *Journal of cellular physiology*. 2018;233(3):2019-31.
169. Ghalamfarsa G, Rastegari A, Atyabi F, Hassannia H, Hojjat-Farsangi M, Ghanbari A, Anvari E, Mohammadi J, Azizi G, Masjedi A. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. *Journal of cellular physiology*. 2018;233(10):7165-77.
170. Dana, Sadoughi, Asemi, **Yousefi B**. Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma. *Current Medicinal Chemistry*, Volume 29, Number 25. <https://doi.org/10.2174/0929867329666220209110009>.
171. Darband SG, Mirza-Aghazadeh-Attari M, Kaviani M, Mihanfar A, Sadighparvar S, **Yousefi B**, Majidinia M. Exosomes: natural nanoparticles as bio shuttles for RNAi delivery. *Journal of Controlled Release*. 2018;289:158-70.
172. Darband SG, Kaviani M, **Yousefi B**, Sadighparvar S, Pakdel FG, Attari JA, Mohebbi I, Naderi S, Majidinia M. Quercetin: a functional dietary flavonoid with potential chemo- preventive properties in colorectal cancer. *Journal of Cellular Physiology*. 2018;233(9):6544- 60.
173. Baghi HB, **Yousefi B**, Mohammadzadeh A, Oskouee MA. Keeping abreast of human papillomavirus in Iran. *European Journal of Cancer Prevention*. 2018;27(6):577.
174. Azimi A, Majidinia M, Shafiei-Irannejad V, Jahanban-Esfahlan R, Ahmadi Y, Karimian A, mostafa Mir S, Karami H, **Yousefi B**. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin. *Gene*. 2018;642:249-55.
175. Alizadeh-Ghodsi M, Zavvari A, Ebrahimi-Kalan A, Shiri-Shahsavari MR, **Yousefi B**. The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary. *Nutritional Neuroscience*. 2018;21(2):92-6.

176. **Yousefi B**, Azimi A, Majidinia M, Shafiei-Irannejad V, Badalzadeh R, Baradaran B, Zarghami N, Samadi N. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR γ -dependent manner in leukemia cells. *Tumor Biology*. 2017;39(10):1010428317716501.
177. Shafiei-Irannejad V, Samadi N, Salehi R, **Yousefi B**, Zarghami N. New insights into antidiabetic drugs: Possible applications in cancer treatment. *Chemical biology & drug design*. 2017;90(6):1056-66.
178. Rahimi M, Shojaei S, Safa KD, Ghasemi Z, Salehi R, **Yousefi B**, Shafiei-Irannejad V. Biocompatible magnetic tris (2-aminoethyl) amine functionalized nanocrystalline cellulose as a novel nanocarrier for anticancer drug delivery of methotrexate. *New Journal of Chemistry*. 2017;41(5):2160-8.
179. Majidinia M, **Yousefi B**. DNA repair and damage pathways in breast cancer development and therapy. *DNA repair*. 2017;54:22-9.
180. Majidinia M, **Yousefi B**. Breast tumor stroma: A driving force in the development of resistance to therapies. *Chemical biology & drug design*. 2017;89(3):309-18.
181. Hosseini, Shanebandi, Soleimanpour, **Yousefi B**, Alemi. Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin. *Drug Res (Stuttg)* 2022; 72(06): 312-318
182. Majidinia M, Alizadeh E, **Yousefi B**, Akbarzadeh M, Mihanfar A, Rahmati-Yamchi M, Zarghami N. Co-inhibition of notch and nf-kb signaling pathway decreases proliferation through downregulating ikb- α and hes-1 expression in human ovarian cancer OVCAR-3 cells. *Drug research*. 2017;67(01):13-9.
183. Karimaian A, Majidinia M, Baghi HB, **Yousefi B**. The crosstalk between Wnt/ β -catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy. *Dna Repair*. 2017;51:14-9.
184. Jahanban-Esfahlan R, Seidi K, Monfaredan A, Shafie-Irannejad V, Abbasi MM, Karimian A, **Yousefi B**. The herbal medicine Melissa officinalis extract effects on gene expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human lung, breast and prostate cancer cell lines. *Gene*. 2017;613:14-9.
185. Baghi HB, **Yousefi B**, Oskouee MA, Aghazadeh M. HPV vaccinations: a Middle Eastern and north African dilemma. *The Lancet Infectious Diseases*. 2017;17(1):18-9.
186. Badalzadeh R, Baradaran B, Alihemmati A, **Yousefi B**, Abbaszadeh A. Troxerutin preconditioning and ischemic postconditioning modulate inflammatory response after myocardial ischemia/reperfusion injury in rat model. *Inflammation*. 2017;40(1):136-43.
187. Badalzadeh R, Azimi A, Alihemmati A, **Yousefi B**. Chronic type-I diabetes could not impede the anti-inflammatory and anti-apoptotic effects of combined postconditioning with ischemia and cyclosporine A in myocardial reperfusion injury. *Journal of physiology and biochemistry*. 2017;73(1):111-20.
188. **Yousefi B**, Zarghami N, Samadi N, Majidinia M. Peroxisome proliferator-activated receptors and their ligands in cancer drug-resistance: opportunity or challenge. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*. 2016;16(12):1541-8.
189. **Yousefi B**, Shafiei-Irannejad V, Azimi A, Samadi N, Zarghami N. PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia. *Cellular and Molecular Biology*. 2016;62(8):52-5.
190. **Yousefi B**, Samadi N, Baradaran B, Shafiei-Irannejad V, Zarghami N. Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: Therapeutic strategies. *Chemical biology & drug design*. 2016;88(1):17-25.
191. Orangi M, Pasdaran A, Shanebandi D, Kazemi T, **Yousefi B**, Hosseini B-A, Baradaran B.

- Cytotoxic and apoptotic activities of methanolic subfractions of *Scrophularia oxysepala* against human breast cancer cell line. *Evidence-Based Complementary and Alternative Medicine*. 2016;2016.
192. Mohseni M, Samadi N, Ghanbari P, **Yousefi B**, Tabasinezhad M, Sharifi S, Nazemiyeh H. Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo- resistance. *Iranian Journal of Basic Medical Sciences*. 2016;19(3):300.
 193. Sadoughi, Asemi, **Yousefi B**, Mansournia, Hallajzade. Cervical Cancer and Novel Therapeutic and Diagnostic Approaches using Chitosan as a Carrier: A Review. *Current Pharmaceutical Design*, 2022. Volume 28, Number 24.
 194. Majidinia M, **Yousefi B**. DNA damage response regulation by microRNAs as a therapeutic target in cancer. *DNA repair*. 2016;47:1-11.
 195. Majidinia M, Alizadeh E, **Yousefi B**, Akbarzadeh M, Zarghami N. Downregulation of notch signaling pathway as an effective chemosensitizer for cancer treatment. *Drug research*. 2016;66(11):571-9.
 196. Karimian A, Ahmadi Y, **Yousefi B**. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. *DNA repair*. 2016;42:63-71.
 197. Ghiasi R, Mohammadi M, Majidinia M, **Yousefi B**, Ghiasi A, Badalzadeh R. The effects of mebudipine on myocardial arrhythmia induced by ischemia-reperfusion injury in isolated rat heart. *Cellular and Molecular Biology*. 2016;62(13):15-20.
 198. Azimi A, Hagh M, **Yousefi B**, Rahnema M, Khorrami A, Heydarabad M, Najafpour M, Hallajzadeh J, Ghahremani A. The effect of prednisolone on miR 15a and miR16-1 expression levels and apoptosis in acute lymphoblastic leukemia cell line: CCRF-CEM. *Drug Research*. 2016;66(08):432-5.
 199. Alizadeh N, Mosaferi E, Farzadi L, Majidi J, Monfaredan A, **Yousefi B**, Baradaran B. Frequency of null allele of human leukocyte antigen-G (HLA-G) locus in subjects to recurrent miscarriage. *International Journal of Reproductive BioMedicine*. 2016;14(7):459.
 200. **Yousefi B**, Samadi N, Baradaran B, Rameshknia V, Shafiei-Irannejad V, Majidinia M, Targhaze N, Zarghami N. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. *Cellular and molecular biology*. 2015;61(8):118-22.
 201. **Yousefi B**, Abasi M, Abbasi MM, Jahanban-Esfahlan R. Anti-proliferative properties of Cornus mass fruit in different human cancer cells. *Asian Pacific Journal of Cancer Prevention*. 2015;16(14):5727-31.
 202. Tabatabaei S, Badalzadeh R, Mohammadnezhad R, **Yousefi B**. Effect of Cinnamon extract on COX-2 gene expression level in liver and lipid profile alterations in serum of healthy broiler chickens and those infected with E. coli. *Veterinary Clinical Pathology The Quarterly Scientific Journal*. 2015;9(1 (33) Spring):61-72.
 203. Seyfizadeh N, Seyfizadeh N, **Yousefi B**, Borzoueisileh S, Majidinia M, Shanehbandi D, Jahani MA. Is there association between ABO blood group and the risk factors of unfavorable outcomes of pregnancy? *The Journal of Maternal-Fetal & Neonatal Medicine*. 2015;28(5):578-82.
 204. Samadi N, Mohseni M, Ganbari P, **Yousefi B**. Abstract A21: Combined treatment increases the efficacy of chemotherapeutics by downregulating of P-glycoprotein. AACR; 2015.
 205. Montazami N, Kheirandish M, Majidi J, Yousefi M, **Yousefi B**, Mohamadnejad L, Shanebandi D, Estiar M, Khaze V, Mansoori B. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells. *Cellular and Molecular Biology*. 2015;61(2):98-103.
 206. Hosseini S, Hashemzadeh S, Estiar MA, Ebrahimzadeh R, Fakhree MBA, **Yousefi B**, Sheikholeslami S, Modarresi MH, Sakhinia E. Expression analysis of aurora-C and Survivin, two

- testis-specific genes, in patients with colorectal cancer. *Clin Lab*. 2015;61(5-6):475-80.
207. Charkhpour M, Ghavimi H, Ghanbarzadeh S, **Yousefi B**, Khorrami A, Mesgari M, Hassanzadeh K. Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. *Journal of biomedical science*. 2015;22(1):1-6.
 208. Badalzadeh R, **Yousefi B**, Tajaddini A, Ahmadian N. Diosgenin-induced protection against myocardial ischaemia-reperfusion injury is mediated by mitochondrial KATP channels in a rat model. *Perfusion*. 2015;30(7):565-71.
 209. Badalzadeh R, Mohammadi M, **Yousefi B**, Farajnia S, Najafi M, Mohammadi S. Involvement of glycogen synthase kinase-3 β and oxidation status in the loss of cardioprotection by postconditioning in chronic diabetic male rats. *Advanced Pharmaceutical Bulletin*. 2015;5(3):321.
 210. Azimi A, Hagh MF, Talebi M, **Yousefi B**, Baradaran B, Movassaghpour AA, Shamsasenjan K, Khanzadeh T, Ghaderi AH, Heydarabad MZ. Time-and concentration- dependent effects of resveratrol on miR 15a and miR16-1 expression and apoptosis in the CCRF-CEM acute lymphoblastic leukemia cell line. *Asian Pacific Journal of Cancer Prevention*. 2015;16(15):6463-8.
 211. Parnia Rahnamay Farnood, Romina Danesh Pazhooh, Zatollah Asemi* and **Yousefi B** *. Targeting Signaling Pathway by Curcumin in Osteosarcoma Curr Mol Pharmacol. 2022
 212. **Yousefi B**, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. *DNA repair*. 2014;22:24-9.
 213. **Yousefi B**, Rahmati M, Ahmadi Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. *Life sciences*. 2014;99(1-2):14-7.
 214. **Yousefi B**, Kokhaei P, Mehranfar F, Bahar A, Abdolshahi A, Emadi A, Eslami M. The role of the host microbiome in autism and neurodegenerative disorders and effect of epigenetic procedures in the brain functions. *Neuroscience & Biobehavioral Reviews*. 2021.
 215. **Yousefi B**, Faghfoori Z, Samadi N, Karami H, Ahmadi Y, Badalzadeh R, Shafiei-Irannejad V, Majidinia M, Ghavimi H, Jabbarpour M. The effects of Ramadan fasting on endothelial function in patients with cardiovascular diseases. *European journal of clinical nutrition*. 2014;68(7):835-9.
 216. **Yousefi B**, Ahmadi Y, Ghorbanihaghjo A, Faghfoori Z. Serum arsenic and lipid peroxidation levels in patients with multiple sclerosis. *Biological trace element research*. 2014;158(3):276-9.
 217. Sepehr KS, Baradaran B, Mazandarani M, **Yousefi B**, Alitappeh MA, Khor V. Growth-inhibitory and apoptosis-inducing effects of Punica Granatum L. var. spinosa (apple punice) on fibrosarcoma cell lines. *Advanced pharmaceutical bulletin*. 2014;4(Suppl 2):583.
 218. Mohammadzadeh R, Baradaran B, Valizadeh H, **Yousefi B**, Zakeri-Milani P. Reduced ABCB1 expression and activity in the presence of acrylic copolymers. *Advanced pharmaceutical bulletin*. 2014;4(3):219.
 219. Ghorbanihaghjo A, Argani H, Samadi N, Valizadeh S, Halajzadeh J, **Yousefi B**, Rashtchizadeh N. Relationship between vitamin D receptor gene FokI and ApaI polymorphisms and serum levels of fetuin-A, vitamin D, and parathyroid hormone in patients on hemodialysis. *Iranian journal of kidney diseases*. 2014;8(5):394-400.
 220. Ghanbari P, Samadi N, Tabasinezhad M, Mohseni M, **Yousefi B**, Rashidi M, editors. Adjuvant therapy improves the chemotherapeutic effect of docetaxel and vinblastine in breast cancer cells. 9th European Breast Cancer Conference (EBCC); 2014.
 221. Ghanbari P, Mohseni M, Tabasinezhad M, **Yousefi B**, Saei AA, Sharifi S, Rashidi MR, Samadi N. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. *Applied biochemistry and biotechnology*. 2014;174(2):667-81.
 222. Ebrahimi H, Badalzadeh R, Mohammadi M, **Yousefi B**. Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium

- channels. *Journal of physiology and biochemistry*. 2014;70(2):425-32.
223. Badalzadeh R, **Yousefi B**, Majidinia M, Ebrahimi H. Anti-arrhythmic effect of diosgenin in reperfusion-induced myocardial injury in a rat model: activation of nitric oxide system and mitochondrial K ATP channel. *The Journal of Physiological Sciences*. 2014;64(6):393-400.
 224. Saliani N, Darabi M, **Yousefi B**, Baradaran B, Khaniani MS, Darabi M, Shaaker M, Mehdizadeh A, Naji T, Hashemi M. PPAR γ agonist-induced alterations in $\Delta 6$ -desaturase and stearyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway. *World journal of hepatology*. 2013;5(4):220.
 225. Vaghari-Tabari M, Moein S, Alipourian A, Qujeq D, Malakoti F, Alemi F, **Yousefi B**, Khazaie S. Melatonin and inflammatory bowel disease: From basic mechanisms to clinical application. *Biochimie*. 2022 Dec 16:S0300-9084(22)00331-5.
 226. Malakoti F, Zare F, Zarezadeh R, Raei Sadigh A, Sadeghpour A, Majidinia M, **Yousefi B**, Alemi F. The role of melatonin in bone regeneration: A review of involved signaling pathways. *Biochimie*. 2022 Nov;202:56-70.
 227. **Yousefi B**, Darabi M, Baradaran B, Khaniani MS, Rahbani M, Darabi M, Fayezi S, Mehdizadeh A, Saliani N, Shaaker M. Inhibition of MEK/ERK1/2 signaling affects the fatty acid composition of HepG2 human hepatic cell line. *BioImpacts: BI*. 2012;2(3):145.
 228. Maleki Dana P, Sadoughi F, Asemi Z, **Yousefi B***. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. *Cell Mol Biol Lett*. 2022;Jan 3;27(1):1
 229. F Malakoti, N Targhazeh, E Abadifard, R Zarezadeh, S Samemaleki, **B Yousefi***. DNA repair and damage pathways in mesothelioma development and therapy. *Cancer Cell International* 22 (1), 1-12. 2022.
 230. Homayoonfal M, Asemi Z, **Yousefi B**. Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. *Cell Mol Biol Lett*. 2022 Mar 2;27(1):21.

PROJECT ADMINSTOR

- Evaluation of the role of miRNA-346 in temozolomide-resistance in cell line of glioblastoma
Sponsor: Tabriz University of Medical Sciences
Year: 2022
Grant amount: IRR 350,000,000
- The effects of thymoquinone in doxorubicin-resistance in glioblastoma cell line
Sponsor: Tabriz University of Medical Sciences
Year: 2021
Grant amount: IRR 180,000,000
- Studying the molecular effect of melatonin on sensitivity of a SW40 colon cancer cell line to etoposide
Sponsor: Tabriz University of Medical Sciences
Year: 2020
Grant amount: IRR 350,000,000
- Evaluation the role of miR-622 by inhibiting the expression of metastatic genes K-Ras, c-

Myc, MMP2 and MMP9 in prostate cancer cell progression

Sponsor: Tabriz University of Medical Sciences

Year: 2020

Grant amount: IRR 180,000,000

- Evaluation of miR-30c expression pattern and its effect on the progression of prostate cancer by targeting PLK1-FOXO1 pathway in DU-145 cell line
Sponsor: Tabriz University of Medical Sciences
Year: 2021
Grant amount: IRR 180,000,000
- Study of the effect of thymoquinone on increasing the sensitivity to 5-fluorouracil in SW-480 colon cancer cells
Sponsor: Tabriz University of Medical Sciences
Year: 2020
Grant amount: IRR 180,000,000
- Evaluation of the role of miR-205-5p in proliferation and susceptibility of prostate cancer cells in the presence of 5-fluorouracil
Sponsor: Tabriz University of Medical Sciences
Year: 2020
Grant amount: IRR 650,000,000
- Investigating the role of Quercetin on expression of miR-22 and genes-related to DNA damage response in osteosarcoma cell line.
Sponsor: Tabriz University of Medical Sciences
Year: 2019
Grant amount: IRR 180,000,000
- Determination of HOTAIRM1 Non-coding RNA Expression and its Relation to Clinical Pathological Findings in Breast Cancer Tumor Specimens
Sponsor: Tabriz University of Medical Sciences
Year: 2019
Grant amount: IRR 120,000,000
- Study the effect of cisplatin with melatonin on expression of miR-181b, CYLD,CBX-7,BCL2 and p53 in MG-63 osteosarcoma cells
Sponsor: Tabriz University of Medical Sciences
Year: 2019
Grant amount: IRR 120,000,000
- Investigating the expression of miR-29, miR346, miR429 and miR-106b In acute Kidney

injury and its relationship with severity disease.

Sponsor: Tabriz University of Medical Sciences

Year: 2019

Grant amount: IRR 160,000,000

- Investigating the role of Thymoquinone in increasing the rate of Cisplatin-induced apoptosis through oxidative DNA damage in Saso-2 cancer cells

Sponsor: Tabriz University of Medical Sciences

Year: 2018

Grant amount: IRR 120,000,000

- Design of magnetism nanoparticles based on cyclodextrin dendritic-graphene oxide with melatonin to enhance the efficacy of doxorubicin to apoptotic processes

Sponsor: Tabriz University of Medical Sciences

Year: 2018

Grant amount: IRR 220,000,000

- Evaluation of miRNA-29a role in doxorubicin drug resistance in HT-29 colon cancer cells

Sponsor: Tabriz University of Medical Sciences

Year: 2018

Grant amount: IRR 250,000,000

- The study of correlation between miR-181 and miR-34a with FGF21, 53BP1 and DNA damage response process in progression of cell aging and cancer proliferation

Sponsor: Tabriz University of Medical Sciences

Year: 2018

Grant amount: IRR 60,000,000

WORKSHOPS

Holding workshop on biomedical research methods in 21st International Physiology and Pharmacology Congress (Iran) including:

- Western blotting,
- Electrophoresis
- qRT-PCR

TEACHING RECORD

- Medical Biochemistry (both theoretical and applied courses) in Tabriz University of Medical Sciences, to the following students and levels:
 - *Doctoral level*: Medicine students - Pharmacology students
 - *MSc level*: Master students of Clinical Biochemistry and Microbiology in faculty of medicine
 - *Bachelor level*: Nursing and Midwifery students; Paramedicine and Laboratory Sciences students
- Molecular Biology: PhD students of Anatomy and Biochemistry
- Metabolism: M.Sc. students

SUPERVISORS

Thesis supervisor for 25 PhD, Msc and MD students.

CLINICAL EXPERIENCE

Skilled in all techniques used in a hospital laboratory. I have been the head of the medical laboratory of Shohada Hospital which is one of the main hospitals in the northwest of Iran. I am responsible for the overall operation and administration of the laboratory, including the employment of competent personnel, equipment, safety, laboratory policies, quality assurance, all testing (including proficiency testing) and test reports. I have been honored many times by the head of the hospital for my good performance. In addition, I was selected and honored as the best young clinical biochemist in our country by Iranian Society of Laboratorian.

REFEREES

- Russel J. Reiter, Chair and Professor
Department of Cellular & Structural Biology,
University of Texas, Health Science Center San Antonio
Email: reiter@uthscsa.edu
- Prof. Behzad Baradaran, Chair and Professor
Immunology Research Center,
Tabriz University of Medical Sciences Tabriz, Iran
Email: behzad_im@yahoo.com
- Prof. Maryam Majidinia, Chair and Professor
Solid Tumor Research Center,
Urmia University of Medical Sciences Urmia, Iran

Email: majidinia25@gmail.com

- Dr. Darioush Shanebandi, Assistant Professor
Immunology Research Center,
Tabriz University of Medical Sciences Tabriz, Iran
Email: dariush_shanebandi@yahoo.com

- Prof. Siavash K. Kurdistani, MD
David Geffen School of Medicine at UCLA,
Department of Biological Chemistry,
University of California, Los Angeles, USA
Email: skurdistani@mednet.ucla.edu